文献速递神经肌肉病神经免疫

调节性T细胞扩增与肌萎缩侧索硬化进展的关联:人类与转基因小鼠模型研究

Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model.
PubMed 文献 · JAMA Neurol · 2018-01-01

该前瞻性多中心人类与动物研究在33例散发性ALS患者和38例健康对照中发现,总调节性T细胞水平(包括效应CD45RO+亚群)与疾病进展速率呈负相关(R=-0.40,P=.002);在SOD1G93A小鼠中,IL-2c扩增效应调节性T细胞可减慢疾病进展并延长生存时间(IL-2c组平均160.6天 vs 对照组144.9天,P=.003)。

要点

  • ALS患者总调节性T细胞水平与疾病进展速率呈负相关(R=-0.40,P=.002)。
  • SOD1G93A小鼠中IL-2c扩增调节性T细胞可减慢进展并延长生存(P=.003)。
  • 调节性T细胞扩增伴随运动神经元胞体大小保留和胶质细胞免疫反应抑制。

核心结论

  • 这些发现确立了调节性T细胞的神经保护作用,可能通过抑制中枢神经系统中有毒神经炎症介导;旨在从外周增强调节性T细胞群和神经保护活性的策略可能对ALS患者有治疗价值。

研究设计与样本

  • 前瞻性多中心人类与动物研究,在医院、门诊诊所和研究机构进行;纳入33例散发性ALS患者,并与2013年2月1日至2014年12月31日期间从Westmead医院多学科ALS门诊连续招募的38例健康对照比较;随后在表达突变超氧化物歧化酶1(SOD1)的转基因小鼠中,通过外周注射白细胞介素2/白细胞介素2单克隆抗体复合物(IL-2c)扩增内源性调节性T细胞群。

主要发现

  • ALS患者队列包括24例男性和9例女性(评估时平均[SD]年龄58.9[10.9]岁)。
  • 总调节性T细胞水平(包括效应CD45RO+亚群)与疾病进展速率呈负相关(R=-0.40,P=.002)。
  • SOD1G93A小鼠中效应调节性T细胞群扩增与疾病进展显著减慢相关,并伴随生存时间延长(IL-2c处理小鼠:平均[SD]160.6[10.8]天;对照小鼠:平均[SD]144.9[10.6]天;P=.003)。
  • 调节性T细胞扩增与SOD1G93A小鼠脊髓中运动神经元胞体大小保留、星形胶质细胞和小胶质细胞免疫反应性显著抑制相关,并伴随脊髓和周围神经中神经营养因子基因表达升高。

临床怎么用

  • 作者认为,旨在从外周增强调节性T细胞群和神经保护活性的策略可能对ALS患者有治疗价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neuroinflammation appears to be a key modulator of disease progression in amyotrophic lateral sclerosis (ALS) and thereby a promising therapeutic target. The CD4+Foxp3+ regulatory T-cells (Tregs) infiltrating into the central nervous system suppress neuroinflammation and promote the activation of neuroprotective microglia in mouse models of ALS. To our knowledge, the therapeutic association of host Treg expansion with ALS progression has not been studied in vivo. OBJECTIVE: To assess the role of Tregs in regulating the pathophysiology of ALS in humans and the therapeutic outcome of increasing Treg activity in a mouse model of the disease. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter human and animal study was performed in hospitals, outpatient clinics, and research institutes. Clinical and function assessment, as well as immunological studies, were undertaken in 33 patients with sporadic ALS, and results were compared with 38 healthy control participants who were consecutively recruited from the multidisciplinary ALS clinic at Westmead Hospital between February 1, 2013, and December 31, 2014. All data analysis on patients with ALS was undertaken between January 2015 and December 2016. Subsequently, we implemented a novel approach to amplify the endogenous Treg population using peripheral injections of interleukin 2/interleukin 2 monoclonal antibody complexes (IL-2c) in transgenic mice that expressed mutant superoxide dismutase 1 (SOD1), a gene associated with motor neuron degeneration. MAIN OUTCOMES AND MEASURES: In patients with ALS, Treg levels were determined and then correlated with disease progression. Circulating T-cell populations, motor neuron size, glial cell activation, and T-cell and microglial gene expression in spinal cords were determined in SOD1G93A mice, as well as the association of Treg amplification with disease onset and survival time in mice. RESULTS: The cohort of patients with ALS included 24 male patients and 9 female patients (mean [SD] age at assessment, 58.9 [10.9] years). There was an inverse correlation between total Treg levels (including the effector CD45RO+ subset) and rate of disease progression (R = -0.40, P = .002). Expansion of the effector Treg population in the SOD1G93A mice was associated with a significant slowing of disease progression, which was accompanied by an increase in survival time (IL-2c-treated mice: mean [SD], 160.6 [10.8] days; control mice: mean [SD], 144.9 [10.6] days; P = .003). Importantly, Treg expansion was associated with preserved motor neuron soma size and marked suppression of astrocytic and microglial immunoreactivity in the spinal cords of SOD1G93A mice, as well as elevated neurotrophic factor gene expression in spinal cord and peripheral nerves. CONCLUSIONS AND RELEVANCE: These findings establish a neuroprotective effect of Tregs, possibly mediated by suppression of toxic neuroinflammation in the central nervous system. Strategies aimed at enhancing the Treg population and neuroprotective activity from the periphery may prove therapeutically useful for patients with ALS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Sheean RK, McKay FC, Cretney E, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018. PMID: 29507931. doi:10.1001/jamaneurol.2018.0035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。